In the classification of clinicopathological features, dysregulated RCCRT1 [23], SPRY4-IT1 [24], H19 [21], NONHSAT123350 [29], and ATB [22] could potentially be exploited as novel biomarkers to detect distant metastasis in patients with RCC in early stages. Here, SPRY4 is linked to renal cell adenocarcinoma.